From Body Positivity to the GLP‑1 Era: Why Thinness Is Back in Fashion and What It Means for You
Explore how the body‑positivity movement gave way to a new thin‑ideal driven by GLP‑1 drugs, fashion, and pharma, and a simple tip to protect your wellbeing this week.
A new paradox
The fashion week in Milan ended with 97.5% of models on the runway in a US size 4 or smaller, while the event listed Eli Lilly – the maker of GLP‑1 weight‑loss drugs – among its sponsors. The clash between a decades‑old body‑positivity narrative and a fresh, drug‑fuelled thinness drive matters because it reshapes what the public, advertisers and health professionals consider “normal” body size.
The rise and fall of mainstream body positivity
During the late 2010s the body‑positivity movement argued that no body type is morally, sexually or aesthetically superior. Activists and early adopters used hashtags like #BoPo on Tumblr and Instagram, celebrating size‑diverse models such as Tess Holliday (size 22) and later Lizzo on the cover of Vogue. Brands – from Dove to Aerie – co‑opted the language to sell products, and luxury magazines began to feature plus‑size covers, albeit often in tokenistic ways.
The mechanism was simple: visibility changes perception. When a reader sees a larger model wearing a familiar brand, the brain updates its statistical model of “typical” bodies, reducing the internalised belief that thinness equals value. Studies from the period show short‑term boosts in body satisfaction after viewing body‑positive images, though the effect often fades within weeks.
Enter the GLP‑1 age
GLP‑1 (glucagon‑like peptide‑1) receptor agonists – drugs originally developed for type 2 diabetes – have been repurposed as powerful weight‑loss agents. Eli Lilly’s Zepbound (semaglutide) and Mounjaro (tirzepatide) are marketed with headlines like “average users lose 15 kg in 16 weeks”. The drugs are now advertised alongside fitness influencers who share “before‑and‑after” photos showing dramatic slimming.
Unlike the earlier movement, the narrative now frames thinness as a health‑optimised, attainable goal. The language shifts from “accept your body” to “optimise your body”, with the implication that the only barrier is access to the drug and the will to invest time and money. This reframing dovetails with fashion’s renewed obsession with ultra‑thin silhouettes, creating a feedback loop: thin models attract drug ads; drug ads fuel the desire for thin models.
Who gains and who loses?
| Stakeholder | Body‑positivity era (≈2015‑2020) | GLP‑1 era (2023‑2026) |
|---|---|---|
| Fashion houses | Gained goodwill by showcasing limited size diversity; often tokenistic. | Benefit from clear aesthetic direction; reduced pressure to produce plus‑size garments. |
| Pharma (Eli Lilly, Novo Nordisk) | Limited relevance to fashion; focused on diabetes market. | New revenue stream from aesthetic‑driven weight‑loss market; brand visibility via fashion sponsorships. |
| Consumers seeking thinness | Limited, often expensive routes (diet, surgery). | Direct pharmacological pathway; rapid results advertised. |
| Plus‑size advocates | Platform for visibility; some policy wins (model health regulations). | Marginalised again; discourse reframed as “stigma” around obesity rather than critique of thinness. |
| Public health system (NHS) | Focus on obesity prevention through lifestyle advice. | New demand for costly GLP‑1 prescriptions; risk of diverting resources from broader health initiatives. |
The trade‑off is clear: the fashion industry saves on production complexity, while pharma captures a lucrative market, but the public loses a balanced conversation about health versus aesthetics.
What could go wrong?
The source leaves several risks unexamined. First, GLP‑1 drugs are prescription‑only and can be expensive; private clinics may market them to affluent consumers, widening health inequities. Second, the emphasis on rapid weight loss can exacerbate body‑image anxiety, especially among young people who see glossy before‑and‑after images. Third, the industry’s focus on “thinness as health” may reinforce weight‑bias among clinicians, contrary to NHS guidance that discourages BMI‑centric treatment pathways.
Moreover, the resurgence of thinness does not automatically solve the systemic issues highlighted by body‑positivity activists – such as the lack of truly inclusive sizing in mainstream retail. Without structural change, the market will continue to cater primarily to size 0‑4, leaving the majority of the population under‑served.
Why the shift matters for everyday health
The NHS still advises that weight management should start with diet, activity, and behavioural support, reserving medication for people with a BMI ≥ 35 kg/m² + related health problems, or BMI ≥ 30 kg/m² with comorbidities. The current cultural pressure to lose the “last 10 lb” pushes people below these thresholds to seek drugs off‑label, a practice the regulator cautions against.
From a physiological perspective, GLP‑1 agonists reduce appetite by acting on hypothalamic receptors and slow gastric emptying, which explains the rapid weight loss. However, the drugs also carry side‑effects – nausea, gallbladder disease, and, in rare cases, pancreatitis – that require medical monitoring. When the motivation is purely aesthetic, patients may downplay these risks or discontinue treatment abruptly, leading to rebound weight gain and psychological distress.
A concrete step you can take this week
If you notice fashion or social‑media content that glorifies extreme thinness, pause and compare it with NHS guidance on healthy weight. Write down one fact‑based question you could ask a GP – for example, “What lifestyle changes are recommended for my BMI of 27 kg/m² before considering medication?” – and bring it to your next appointment. Having a concrete, health‑focused question helps steer the conversation away from aesthetic pressures and back to evidence‑based care.
